Medidata Study Experience

  1. How To Double High-Performing Site Count In A Priority Indication 3/13/2023

    A top 10 biopharmaceutical company wanted to expand its site list in a priority indication and better understand how existing sites in their database performed. Find out what happened next.

  2. The State Of Black Participation In Clinical Trials 2/24/2023

    The need to design trials enrolling more demographically diverse patients is widely recognized. Learn why implementing effective, sustainable, and scalable enrollment diversity strategies remains a challenge for biopharmaceutical companies.

  3. Intelligent Trials - Diversity 2/17/2023

    Medidata AI’s Intelligent Trials solution provides insights that allow you to take action to improve study diversity during the planning stages.

  4. New Therapeutic And Diagnostic Avenues In Breast Cancer 1/24/2023

    This podcast discusses an important metastatic breast cancer study that was recently published in the New England Journal of Medicine and presented at ASCO - the American Society of Clinical Oncology in June 2022.

  5. A New Avenue In Breast Cancer Therapeutics 1/23/2023

    Clinical trial findings may have unlocked a groundbreaking opportunity for breast cancer patients: beneficial therapy for HER2-negative patients with HER2-directed antibody-drug conjugates.

  6. 3 Data Linkage Use Cases To Future Proof Your Clinical Trials 12/20/2022

    Discover why access to compelling and relevant evidence is crucial to drug development, safety monitoring, and improved patient outcomes. 

  7. The Future Of Data Linkage In Clinical Trial Evidence Generation 12/20/2022

    Explore key questions about the future of AI and data linkage in clinical trial evidence generation.

  8. Imunon Phase IB Ovarian Cancer Study Shows Strong Progression-Free Survival Treatment Effect Using A Synthetic Control Arm 12/8/2022

    Explore how Imunon used a control arm among stage III/IV ovarian cancer patients in their clinical trial.

  9. A Mid-Sized Sponsor Increased Site Count By 50% In A Rare Disease Clinical Trial 12/8/2022

    In this case study, explore how a mid-sized sponsor chose high-performing sites based on reliable data to set their trial up for success.

  10. Medicenna Gains Precedent-Setting FDA Approval 12/8/2022

    Learn how Medicenna was able to leverage Synthetic Control Arm (SCA) to bolster Phase 2 findings and gain FDA approval to design a hybrid external control arm for their Phase 3 registrational trial.